Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults

Dermatology

Volumn 214, Issue 4, 2007, Pages 289-295

  Margolis, David J ^a   Hoffstad, Ole ^a   Bilker, Warren ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Atopic dermatitis; Calcineurin inhibitors; Case control study; Nonmelanoma skin cancer; Pimecrolimus; Tacrolimus

Indexed keywords

CALCINEURIN INHIBITOR; PIMECROLIMUS; TACROLIMUS;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATOPIC DERMATITIS; CANCER RISK; COMPARATIVE STUDY; CONTROLLED STUDY; DERMATITIS; DRUG EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; SEX DIFFERENCE; SKIN CANCER;

ADMINISTRATION, TOPICAL; AGED; CALCINEURIN; CASE-CONTROL STUDIES; DERMATITIS, ATOPIC; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; SKIN NEOPLASMS; TACROLIMUS;

EID: 34247522722     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100879     Document Type: Article

References (36)

1. Jourdan-Da SN, Perel Y, Mechinaud F, et al: Infectious diseases in the first year of life, perinatal characteristics and childhood acute leukaemia. Br J Cancer 2004;90:139-45.
2. Mehrany K, El-Azhary RA, Bouwhuis SA, Pittelkow MR: Cutaneous T-cell lymphoma and atopy: is there an association? Br J Dermatol 2003;149:1013-1017.
3. Bernard LA, Eichenfield LF: Topical immunomodulators for atopic dermatitis. Curr Opin Pediatr 2002;14:414-418.
4. Berg D, Otley CC: Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. Je Am Acad Dermatol 2002;47:1-17.
5. Ormerod AD: Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol 2005;153:701-705.
6. USP DI, ed 23. Greenwood Village, Micromedex Thomson Healthcare, 2003.
7. Sturgill S, Bernard LA: Atopic dermatitis update. Curr Opin Pediatr 2004;16:396-401.
8. Saurat JH, Hanifin JM: Understanding atopic dermatitis: pathophysiology and etiology (Conclusion). J Am Acad Dermatol 2001;45(suppl 1):S67-S68.
9. Williams HC: Epidemiology of atopic dermatitis. Clin Exp Dermatol 2000;25:522-529.
10. Hanifin JM, Cooper KD, Ho VC, et al: Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association 'Administrative Regulations for Evidence-Based Clinical Practice Guidelines'. J Am Acad Dermatol 2004;50:391-404.
11. Ming ME, Levy R, Hoffstad O, et al: The lack of a relationship between atopic dermatitis and nonmelanoma skin cancers. J Am Acad Dermatol 2004;50:357-362.
12. Milan T, Verkasalo PK, Kaprio J, Koskenvuo M: Lifestyle differences in twin pairs discordant for basal cell carcinoma of the skin. Br J Dermatol 2003;149:115-123.
13. Hagstromer L, Ye W, Nyren O, Emtestam L: Incidence of cancer among patients with atopic dermatitis. Archf Dermatol 2005;141:1123-1127.
14. Niwa Y, Terashima T, Sumi H: Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol 2003;149:960-967.
15. Girardi M, Glusac E, Filler RB, et al: The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer. J Exp Med 2003;198:747-755.
16. Lubbe J, Sorg O: Tacrolimus ointment and skin carcinogenesis in the DMBA/TPA model in mice (comment). Br J Dermatol 2004;151:1275-1276.
17. Doelker L, Tran C, Gkomouzas A, et al: Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients. Exp Dermatol 2006;15:342-346.
18. Tran C, Lubbe J, Sorg O, et al: Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis. Dermatology 2005;211:341-347.
19. Lubbe J, Sorg O: Tacrolimus ointment and skin carcinogenesis in the DMBA/TPA model in mice (comment). Br J Dermatol 2004;151:1275-1276.
20. Orlow S: Topical cancineurin inhibitors and black boxes. Skin Allergy News 2006;37:14.
21. Dillman DA: Mail and Internet Surveys. The Tailored Design Method, ed 2. New York, Wiley & Sons, 2000.
22. Ming ME, Levy RM, Hoffstad OJ, Filip J, Gimotty PA, Margolis DJ: Validity of patient self-reported history of skin cancer. Arch Dermatol 2004;140:730-735.
23. Fleming S, Bodner C, Devereux G, et al: An application of the United Kingdom Working Party diagnostic criteria for atopic dermatitis in Scottish infants. J Invest Dermatol 2001;117:1526-1530.
24. Hoare C, Li Wan Po A, Williams H: Systemic review of treatments for atopic eczema. Health Technol Assess 2002;4:1-191.
25. Diepgen TL, Mahler V: The epidemiology of skin cancer. Br J Dermatol 2002;146(suppl 61):1-6.
26. Maldonado G, Greenland S: Simulation study of confounder-selection strategies. Am J Epidemiol 1993;138:923-936.
27. Mickey RM, Greenland S: The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989;129:125-37.
28. Liang KY, Zeger SL: Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
29. Al-Daraji WI, Grant KR, Ryan K, Saxton A, Reynolds NJ: Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A. J Invest Dermatol 2002;118:779-788.
30. Fishelevich R, Malanina A, Luzina I, et al: Ceramide-dependent regulation of human epidermal keratinocyte CD1d expression during terminal differentiation. J Immunol 2006;176:2590-2599.
31. Gafter-Gvili A, Sredni B, Gal R, et al: Cyclosporin A-induced hair growth in mice is associated with inhibition of calcineurin-dependent activation of NFAT in follicular keratinocytes. Am J Physiol Cell Physiol 2003;284:C1593- C1603.
32. Mammucari C, di Vignano AT, Sharov AA, et al: Integration of Notch 1 and calcineurin/NFAT signaling pathways in keratinocyte growth and differentiation control. Dev Cell 2005;8:665-676.
33. Reynolds NJ, Al-Daraji WI: Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin Exp Dermatol 2002;27:555-561.
34. Santini MP, Talora C, Seki T, et al: Cross talk among calcineurin, Sp1/Sp3, and NFAT in control of p21(WAF1/CIP1) expression in keratinocyte differentiation. Proc Natl Acad Sci USA 2001;98:9575-9580.
35. Greenland S: Basic Methods for sensitivity analysis of biases. Int J Epidemiol 1996;25:1107-1116.
36. Schlesselman JJ: Case-Control Studies. Design, Conduct, Analysis, ed 1. New York, Oxford University Press, 1982.